View ValuationOncopeptides 향후 성장Future 기준 점검 2/6Oncopeptides은 연간 수입과 매출이 각각 67.9%와 45.5% 증가할 것으로 예상되고 EPS는 연간 70.6%만큼 증가할 것으로 예상됩니다.핵심 정보67.9%이익 성장률70.63%EPS 성장률Biotechs 이익 성장9.2%매출 성장률45.5%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트23 Jun 2026최근 향후 성장 업데이트Breakeven Date Change • May 19Forecast to breakeven in 2028The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 76% per year to 2027. The company is expected to make a profit of kr41.0m in 2028. Average annual earnings growth of 104% is required to achieve expected profit on schedule.Breakeven Date Change • Feb 19No longer forecast to breakevenThe 2 analysts covering Oncopeptides no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr39.3m in 2027. New consensus forecast suggests the company will make a loss of kr1.00m in 2027.공고 • Jan 17Oncopeptides AB (Publ) Provides Sales Guidance for the Fourth Quarter and Full Year 2025Oncopeptides AB (publ) provided sales guidance for the fourth quarter and full year 2025. For the quarter company expects net sales for the second quarter to amount to SEK 18.6 million an increase of 88% versus Fourth Quarter 2024. For the full year, the company expects net sales to amount to 71.2 million SEK, an increase of 125% versus 2024.Breakeven Date Change • Aug 25Forecast to breakeven in 2027The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% per year to 2026. The company is expected to make a profit of kr13.0m in 2027. Average annual earnings growth of 79% is required to achieve expected profit on schedule.Breakeven Date Change • May 21Forecast to breakeven in 2027The 3 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 41% per year to 2026. The company is expected to make a profit of kr2.59m in 2027. Average annual earnings growth of 70% is required to achieve expected profit on schedule.공고 • Apr 05Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024Oncopeptides AB (publ) provided sales guidance for the first quarter of 2024. The company expected net sales to amount to SEK 5.1 million (SEK 1.1 million).모든 업데이트 보기Recent updates공고 • Jun 17Oncopeptides AB (Publ) Announces Enrollment of First Patient in Oncopeptides' Glioblastoma StudyOncopeptides AB (publ) announced that the first patient has been enrolled in the clinical "Window-of-Opportunity" (WoO) study evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma. The WoO study, named OP-701 (INSULA), represents the first clinical evaluation of a PDC in glioblastoma, marking a major strategic milestone as Oncopeptides expands its core technology platform beyond multiple myeloma. The focused trial will enroll approximately 10 patients to provide initial human proof-of-concept to assess that the company's technology successfully penetrates the human blood-brain barrier (BBB) in glioblastoma patients and have cytotoxic (cell killing) activity in tumor cells. The BBB remains the primary clinical obstacle and causes most traditional oncological drugs to fail in this disease. By utilizing an approved drug from Oncopeptides' platform as a "clinical probe," the study employs an innovative and highly efficient design to capture drug activity directly within the tumor tissue from patients scheduled for surgery for recurrent disease. This approach aims to validate the underlying biological mechanism in a rapid, cost-efficient manner before advancing a PDC asset into formal dose-finding and potential further clinical trials. Glioblastoma is the most aggressive and devastating form of brain cancer, characterized by rapid tumor growth, invariable relapse, and a total lack of curative options, with a median survival rate of just 12–15 months. The global glioblastoma market represents a profound unmet medical need and is estimated to be worth more than 8 billion USD by 2035. Oncopeptides' PDC molecules are believed to be uniquely equipped to pass the blood-brain barrier due to their small size and lipophilicity, entering the target cancer cells freely to deliver their cytotoxic payload directly where it is needed. The trial is conducted at Oslo University Hospital in Norway.공고 • May 22Oncopeptides AB Announces Publication of Phase 2 Bridge Study Results for Pepaxti in Relapsed Refractory Multiple Myeloma Patients with Renal ImpairmentOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, announced the publication of the results from the Phase 2 BRIDGE (OP-107) clinical study in the peer-reviewed journal Clinical Lymphoma, Myeloma and Leukemia. The prospective, open-label study evaluated the pharmacokinetics (PK), safety, and efficacy of Pepaxti (melflufen) plus dexamethasone in relapsed, refractory multiple myeloma (RRMM) patients with moderate-to-severe renal impairment (RI). Patients with renal insufficiency represent roughly half of all myeloma diagnoses and typically suffer from poorer long-term outcomes and limited clinical options. The final analyses demonstrate that while systemic exposure to the active metabolite melphalan varies based on baseline kidney function, a reduced melflufen starting dose of 30 mg in patients with moderate renal impairment delivers a consistent safety profile, treatment responses, and survival measures aligned with prior trials conducted in less selected populations. Furthermore, exploratory data gathered across the treatment cycles showed that renal function remained stable or slightly improved during therapy, suggesting that Pepaxti does not adversely impact the kidneys at the studied doses. Validated dose optimization: The PK data directly validate the clinical use and efficacy of a 30 mg Pepaxti starting dose for patients with moderate renal impairment (eGFR =30 to <45 mL/min/1.73 m²). Sustained efficacy in fragile populations: Patients with moderate renal impairment achieved an Overall Response Rate (ORR) of 47.6% in Cohort 1a (40 mg starting dose) and 70.0% in Cohort 1b (30 mg starting dose), with a median progression-free survival (PFS) of 8.6 months and 7.7 months, respectively. No new safety signals: Despite advanced renal impairment and high treatment exposure, the safety profile was well-characterized and manageable. The most frequently reported treatment-emergent adverse events were hematological (thrombocytopenia, anemia, and neutropenia), which is consistent with previous clinical trials. The full article, titled "BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function," is available online via Clinical Lymphoma, Myeloma and Leukemia. Pepaxti (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.Breakeven Date Change • May 19Forecast to breakeven in 2028The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 76% per year to 2027. The company is expected to make a profit of kr41.0m in 2028. Average annual earnings growth of 104% is required to achieve expected profit on schedule.Reported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: kr25.4m (up 91% from 1Q 2025). Net loss: kr32.2m (loss narrowed 47% from 1Q 2025). Revenue is forecast to grow 64% p.a. on average during the next 2 years, compared to a 11% decline forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.공고 • Apr 16Oncopeptides AB (publ), Annual General Meeting, May 21, 2026Oncopeptides AB (publ), Annual General Meeting, May 21, 2026, at 14:00 W. Europe Standard Time. Location: tandstickspalatset, vastra, tradgardsgatan 15, stockholm SwedenNew Risk • Apr 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 84% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-kr59m). Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr19m net loss in 2 years). Market cap is less than US$100m (kr573.2m market cap, or US$60.8m).New Risk • Mar 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 84% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-kr59m). Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr19m net loss in 2 years). Market cap is less than US$100m (kr596.9m market cap, or US$64.2m).공고 • Mar 18Oncopeptides AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 200.389791 million.Oncopeptides AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 200.389791 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 129,283,736 Price\Range: SEK 1.55 Transaction Features: Rights OfferingReported Earnings • Feb 20Full year 2025 earnings released: kr1.10 loss per share (vs kr1.71 loss in FY 2024)Full year 2025 results: kr1.10 loss per share (improved from kr1.71 loss in FY 2024). Revenue: kr71.1m (up 125% from FY 2024). Net loss: kr249.6m (loss narrowed 12% from FY 2024). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 3.1% decline forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.New Risk • Feb 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr45m net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (kr749.9m market cap, or US$82.8m).Breakeven Date Change • Feb 19No longer forecast to breakevenThe 2 analysts covering Oncopeptides no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr39.3m in 2027. New consensus forecast suggests the company will make a loss of kr1.00m in 2027.공고 • Feb 19+ 4 more updatesOncopeptides AB (publ) to Report Q2, 2026 Results on Aug 27, 2026Oncopeptides AB (publ) announced that they will report Q2, 2026 results on Aug 27, 2026공고 • Jan 17Oncopeptides AB (Publ) Provides Sales Guidance for the Fourth Quarter and Full Year 2025Oncopeptides AB (publ) provided sales guidance for the fourth quarter and full year 2025. For the quarter company expects net sales for the second quarter to amount to SEK 18.6 million an increase of 88% versus Fourth Quarter 2024. For the full year, the company expects net sales to amount to 71.2 million SEK, an increase of 125% versus 2024.New Risk • Jan 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr268m Forecast net loss in 2 years: kr4.9m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr228m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr4.9m net loss in 2 years). Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding).공고 • Jan 16Oncopeptides AB (publ) to Report Fiscal Year 2025 Results on Feb 19, 2026Oncopeptides AB (publ) announced that they will report fiscal year 2025 results on Feb 19, 2026New Risk • Nov 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr228m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr228m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).Reported Earnings • Nov 06Third quarter 2025 earnings released: kr0.27 loss per share (vs kr0.29 loss in 3Q 2024)Third quarter 2025 results: kr0.27 loss per share. Revenue: kr20.2m (up 138% from 3Q 2024). Net loss: kr60.9m (loss widened 1.1% from 3Q 2024). Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the United Kingdom.New Risk • Oct 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-kr67m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr35m net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding).Recent Insider Transactions • Sep 01Chief Executive Officer recently bought kr250k worth of stockOn the 26th of August, Sofia Heigis bought around 57k shares on-market at roughly kr4.40 per share. This transaction amounted to 65% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Sofia's only on-market trade for the last 12 months.공고 • Sep 01Oncopeptides AB (publ) Announces the Publication of Two Real-World Evidence (RWE) Abstracts on Pepaxti At the International Myeloma Society Annual MeetingOncopeptides AB (publ) announced the publication of two real-world evidence (RWE) abstracts on Pepaxti at the International Myeloma Society (IMS) Annual Meeting, September 17-20 in Toronto, Canada. As previously communicated, the data were generated through treatment outcomes in real world settings from centers in Valencia, Spain and Bologna, Italy and underscore the growing interest in real-world clinical use of Pepaxti. The Italian study reports an overall response rate (ORR) of 47% in a heavily pretreated patient population with relapsed or refractory multiple myeloma, confirming the efficacy previously demonstrated in the HORIZON trial with a similar safety profile. Importantly, the study demonstrated efficacy in patients treated with novel immunotherapies, underscoring the robust effectiveness of Pepaxti in daily clinical practice. The Spanish study confirms the efficacy of Pepaxti in an even more heavily pretreated patient population where the majority of patients had been exposed to either anti-BCMA or anti-GPRC5D immunotherapy, generating data highly relevant to clinicians seeking guidance for treatment decisions. Both studies confirm Pepaxti's favorable tolerability profile in real-world settings - a key consideration in multiple myeloma where safety challenges are common.Breakeven Date Change • Aug 25Forecast to breakeven in 2027The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% per year to 2026. The company is expected to make a profit of kr13.0m in 2027. Average annual earnings growth of 79% is required to achieve expected profit on schedule.Reported Earnings • Aug 22Second quarter 2025 earnings released: kr0.30 loss per share (vs kr0.48 loss in 2Q 2024)Second quarter 2025 results: kr0.30 loss per share (improved from kr0.48 loss in 2Q 2024). Revenue: kr19.2m (up 135% from 2Q 2024). Net loss: kr62.8m (loss narrowed 14% from 2Q 2024). Revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.공고 • Aug 22Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 150.232109 million.Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 150.232109 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 46,947,534 Price\Range: SEK 3.2 Transaction Features: Rights OfferingBuy Or Sell Opportunity • Aug 11Now 21% undervaluedOver the last 90 days, the stock has risen 142% to kr4.71. The fair value is estimated to be kr5.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 8.9% over the last 3 years. Earnings per share has grown by 86%. Revenue is forecast to grow by 569% in 2 years. Earnings are forecast to grow by 73% in the next 2 years.공고 • Jul 23Oncopeptides AB (publ) Announces Acceptance of Spanish and Italian Real-World Data at IMS Annual MeetingOncopeptides AB (publ) announced that two real-world evidence (RWE) posters have been accepted for presentation at the upcoming International Myeloma Society (IMS) Annual Meeting, taking place in Toronto, Canada on September 17-20. The data were generated through treatment outcomes in real world settings from centers in Valencia, Spain and Bologna, Italy and underscore the growing interest in real-world clinical use of Pepaxti. The accepted posters focus on real-world outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma. While specific results will be shared at the congress, the inclusion of these patient cases reflects the increasing importance of RWE to guide treatment decisions in clinical practice. For a medicine with limited awareness and use to date, real-world data play a key role in building physician confidence and informing market access. The inclusion of these two posters at IMS follows a growing body of independent research that reflects clinical experiences across Europe.공고 • Jul 10+ 1 more updateOncopeptides AB (Publ) Announces Inclusion of Drug Pepaxti in New Clinical Practice Guidelines from Eha-EmnOncopeptides AB (publ) announced that its drug Pepaxti has been included in new clinical practice guidelines from EHA-EMN for patients with relapsed, refractory multiple myeloma. This marks an important recognition by leading experts of the drug's clinical value and ability to meet an unmet medical need in the treatment of this serious blood cancer. The guidelines are based on a thorough evaluation of clinical evidence by leading experts and aim to support doctors in selecting appropriate therapies for their patients. For patients who have received multiple prior lines of therapy and are triple-class refractory /exposed (TCR/TCE) - meaning their disease no longer responds to three major classes of myeloma drugs - Pepaxti is recommended based on Level 1 evidence, the strongest possible, and has a Grade B recommendation. Furthermore, Pepaxti has also been listed as a treatment option for patients with even more advanced disease, TCR/TCE patients relapsing after immunotherapy with either CART cells or ADC and whose disease no longer responds to four drug classes.공고 • May 22Oncopeptides AB (publ) Approves Election of Christine Rankin as Board MemberThe Annual General Meeting in Oncopeptides AB (publ) was held on 22 May 2025, approved election of Christine Rankin as board members.Breakeven Date Change • May 21Forecast to breakeven in 2027The 3 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 41% per year to 2026. The company is expected to make a profit of kr2.59m in 2027. Average annual earnings growth of 70% is required to achieve expected profit on schedule.Reported Earnings • May 16First quarter 2025 earnings released: kr0.29 loss per share (vs kr0.72 loss in 1Q 2024)First quarter 2025 results: kr0.29 loss per share (improved from kr0.72 loss in 1Q 2024). Revenue: kr13.3m (up 162% from 1Q 2024). Net loss: kr60.7m (loss narrowed 10% from 1Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.공고 • May 15+ 1 more updateOncopeptides AB (publ) to Report Q3, 2025 Results on Nov 05, 2025Oncopeptides AB (publ) announced that they will report Q3, 2025 results on Nov 05, 2025공고 • May 06Oncopeptides AB's Ordinary Shares to be Deleted from OTC EquityOncopeptides AB (publ) Ordinary Shares will be deleted from OTC Equity effective May 06, 2025, due to inactive security.공고 • Apr 17Oncopeptides AB (publ), Annual General Meeting, May 22, 2025Oncopeptides AB (publ), Annual General Meeting, May 22, 2025, at 10:00 W. Europe Standard Time. Location: at tandstickspalatset, vastra tradgardsgatan 15, stockholm Sweden공고 • Apr 16Oncopeptides AB (publ) Announces the Publication of New Real-World Data That Further Support the Effectiveness and Tolerability of Melflufen, Refractory Multiple MyelomaOncopeptides AB (publ) announced the publication of new real-world data that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM). The data were presented in an abstract from the University of Catania, Italy. It highlights treatment outcomes in a single-center real-world setting. The retrospective analysis included eight triple-class refractory RRMM patients who had received a median of 3.5 prior lines of therapy. Notably, several patients presented with high-risk features, including extramedullary disease. Despite this, treatment with Pepaxti in combination with dexamethasone showed an overall response rate (ORR) of 37.5%, with partial responses seen even among patients with advanced disease manifestations. The data underline Pepaxti's role as a viable treatment option for patients with advanced RRMM for patients who have received at least three prior lines of therapy and whose disease has progressed on or after the last therapy.Board Change • Mar 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 2 highly experienced directors. Independent Director Jennifer Jackson was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Mar 03Oncopeptides AB (publ) to Report Q1, 2025 Results on May 15, 2025Oncopeptides AB (publ) announced that they will report Q1, 2025 results on May 15, 2025New Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr261m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr261m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (127% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr25m net loss in 3 years). Revenue is less than US$5m (kr32m revenue, or US$2.9m). Market cap is less than US$100m (kr342.6m market cap, or US$31.8m).Reported Earnings • Mar 02Full year 2024 earnings released: kr1.71 loss per share (vs kr2.76 loss in FY 2023)Full year 2024 results: kr1.71 loss per share. Revenue: kr31.6m (down 10% from FY 2023). Net loss: kr284.6m (loss widened 14% from FY 2023). Revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the United Kingdom.공고 • Feb 20Oncopeptides AB (publ) to Report Q4, 2024 Results on Feb 27, 2025Oncopeptides AB (publ) announced that they will report Q4, 2024 results at 8:00 AM, Central European Standard Time on Feb 27, 2025공고 • Feb 06Jarl Ulf Jungnelius Resigns from Oncopeptides AB (publ) Board of DirectorsOncopeptides AB (publ) announced that Jarl Ulf Jungnelius has informed the Board of Directors of his decision to step down from the Bord of Directors of Oncopeptides in which he has served since 2011. This due to personal reasons related to a change of domicile from Sweden.New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (127% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr131m net loss in 2 years). Revenue is less than US$5m (kr27m revenue, or US$2.4m). Market cap is less than US$100m (kr339.6m market cap, or US$30.6m).공고 • Jan 27Oncopeptides' Pepaxti Formally Approves for Full Reimbursement in ItalyOncopeptides AB (publ) announced that the positive reimbursement decision for its drug Pepaxti (melflufen) has been published in the Italian Official Journal ("IOJ", It.: Gazetta Ufficiale). This marks the final regulatory step for the drug's upcoming commercialization in Italy, confirming Oncopeptides' expectation of first sales during first half, 2025. With the IOJ publication, Oncopeptides can now initiate the regional access process to bring Pepaxti to patients. The company's goal is to make the treatment available to eligible Italian patients with relapsed and refractory multiple myeloma over the coming months. Italy reports an annual incidence of approximately 6,000 new cases of multiple myeloma, and with about 1,800 patients falling within Pepaxti's target population. 79 patients across 10 Italian hospitals during the clinical development of Pepaxti and 86 treated patients in the Early Access Program (EAP) underscores the clinical experience in the country and high unmet need for the drug. The Early Access program have been closed following the reimbursement. As previously communicated, Oncopeptides is currently in the process of strengthening its presence in Italy by expanding its team and investing in initiatives to raise awareness about Pepaxti and its benefits.Board Change • Jan 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 2 highly experienced directors. Independent Director Jennifer Jackson was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 08Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.45 loss in 3Q 2023)Third quarter 2024 results: kr0.29 loss per share. Revenue: kr8.51m (up 203% from 3Q 2023). Net loss: kr60.2m (loss widened 49% from 3Q 2023). Revenue is forecast to grow 91% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the United Kingdom.New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (127% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr134m net loss in 2 years). Share price has been volatile over the past 3 months (9.1% average weekly change). Revenue is less than US$5m (kr21m revenue, or US$2.0m). Market cap is less than US$100m (kr343.4m market cap, or US$32.1m).Reported Earnings • Aug 19Second quarter 2024 earnings released: kr0.48 loss per share (vs kr0.60 loss in 2Q 2023)Second quarter 2024 results: kr0.48 loss per share. Net loss: kr73.2m (loss widened 30% from 2Q 2023). Revenue is forecast to grow 78% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the United Kingdom.공고 • Jul 04An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million.An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million on July 2, 2024. Industrifonden Foundation has divested its entire stake in Oncopeptides. An undisclosed buyer completed the acquisition of 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden on July 2, 2024.Reported Earnings • Jun 04First quarter 2024 earnings released: kr0.75 loss per share (vs kr0.75 loss in 1Q 2023)First quarter 2024 results: kr0.75 loss per share (improved from kr0.75 loss in 1Q 2023). Revenue: kr5.07m (up 351% from 1Q 2023). Net loss: kr67.7m (loss narrowed 4.7% from 1Q 2023). Revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the United Kingdom.공고 • May 17Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy CongressOncopeptides AB (publ) announced that new scientific data on melflufen, branded in Europe as Pepaxti, has been accepted at the 10th annual World Congress on Cont Cont Cont Controversies in Multiple Myeloma (COMy), to be held on May 23-26. The study, published by a team from institutions across Europe, including the University of Wurzburg and the Institute for Molecular Medicine Finland, focuses on the effectiveness of melflufen and shows promising results for the drug when treating patients with a particularly challenging form of multiple myeloma. The study will be presented to congress attendees through an online oral presentation on May 26. The presentation will be given by Caroline Heckman, from the Institute for Molecular Medicine Finland. Multiple myeloma can be especially difficult to treat in patients who have specific genetic mutations or deletions, such as del(17p) and/or mutations in the TP53 gene. These genetic characteristics are associated with a poorer prognosis and shorter survival rates. The research findings indicate that melflufen is more effective than traditional alkylating agents causing DNA damage and promoting the death of cancer cells lacking a functional so-called p53 protein, which is a common issue in high-risk multiple myeloma cases. The study also highlighted significant changes in gene expression that enhance the drug's impact on cancer cells. Furthermore, patients with the del(17p) genetic abnormality treated with melflufen and dexamethasone showed a longer progression-free survival and higher overall response rate compared to those treated with pomalidomide and dexamethasone in the OP-103 OCEAN trial.New Risk • May 08New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 133% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (133% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr66m net loss in 3 years). Revenue is less than US$5m (kr35m revenue, or US$3.2m). Market cap is less than US$100m (kr637.2m market cap, or US$58.5m).New Risk • Apr 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr50m net loss in 3 years). Shareholders have been diluted in the past year (4.7% increase in shares outstanding). Revenue is less than US$5m (kr35m revenue, or US$3.3m). Market cap is less than US$100m (kr511.6m market cap, or US$48.4m).공고 • Apr 05Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024Oncopeptides AB (publ) provided sales guidance for the first quarter of 2024. The company expected net sales to amount to SEK 5.1 million (SEK 1.1 million).공고 • Mar 13Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Rights OfferingNew Risk • Feb 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr279m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr279m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr50m net loss in 3 years). Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (kr35m revenue, or US$3.4m). Market cap is less than US$100m (kr487.2m market cap, or US$47.1m).공고 • Feb 24Oncopeptides AB (publ), Annual General Meeting, May 22, 2024Oncopeptides AB (publ), Annual General Meeting, May 22, 2024.공고 • Dec 16Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier LinesOncopeptides announced that the European Commission has decided to formally approve the company’s application to the European Medicines Agency (EMA) for an extended indication for Pepaxti into earlier lines. The previously communicated decision by Oncopeptides to opt out of the process to extend the indication remains. Oncopeptides has submitted an application to adjust the indication of Pepaxti to the originally approved indication, a process that is expected to be finalized in early 2024. During this time, Oncopeptides will work together with the European Commission, EMA as well as local stakeholders to ensure an efficient removal process for the extended indication.공고 • Nov 18Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024Oncopeptides AB (publ) announced that they will report Q3, 2024 results on Nov 07, 2024공고 • Nov 15Oncopeptides Selects to Present Additional Data from Ocean StudyOncopeptides AB (publ) announced that long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at the 65th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego between December 9-12. ASH is the world's professional hematologic society serving both clinicians and scientists around the world who are working to conquer blood diseases. The phase 3 OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.New Risk • Nov 09New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr304m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr304m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr147m net loss in 2 years). Share price has been volatile over the past 3 months (9.9% average weekly change). Revenue is less than US$5m (kr29m revenue, or US$2.7m). Market cap is less than US$100m (kr661.4m market cap, or US$61.0m).공고 • Oct 27Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024Oncopeptides AB (publ) announced that they will report Q2, 2024 results at 8:00 AM, Central European Standard Time on Aug 14, 2024공고 • Oct 21Oncopeptides AB (publ) Announces the Nomination CommitteeOncopeptides AB (publ) announces that the composition of the Nomination Committee has been established. According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2024 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of the end of the third quarter 2023 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors. The Nomination Committee in respect of the annual general meeting 2024 consists of the following persons who together represent approximately 29 percent of the number of shares and votes in the company based on the shareholder information at end of September 2023. Staffan Lindstrand, appointed by HealthCap VI L.P., Patrik Sobocki, appointed by Stiftelsen Industrifonden, Caroline Mebius, appointed by Handelsbanken funds, and Per Wold-Olsen, the Chairman of the Board.공고 • Oct 12Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024Oncopeptides AB (publ) announced that they will report Q1, 2024 results on May 03, 2024공고 • Oct 02Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024Oncopeptides AB (publ) announced that they will report fiscal year 2023 final results on Apr 22, 2024공고 • Sep 21Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024Oncopeptides AB (publ) announced that they will report fiscal year 2023 results on Feb 27, 2024공고 • Sep 15Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial ResultsOncopeptides AB (publ) announced that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), has, following their scientific assessment, adopted a positive opinion on Oncopeptides' application for earlier lines of treatment for patients with relapsed, refractory multiple myeloma (RRMM). The opinion from the CHMP will now be sent to the European Commission for a final decision. Based on findings from its OCEAN trial, Oncopeptides submitted, on 28 Nov. 2022, an application to extend the therapeutic indication of Pepaxti to the treatment of adult patients with multiple myeloma who have received at least two prior lines of therapies, whose disease is refractory to lenalidomide and the last line of therapy. With their opinion, CHMP recommends that the use of Pepaxti could be expanded to earlier lines of treatment and also peripheral administration, meaning delivery of treatment through peripheral rather than central veins, a less invasive way of administration. Oncopeptides will as a next step assess the current market dynamics of the rapidly evolving multiple myeloma landscape, including the competition in different lines of treatment and the effect that extending Pepaxti into earlier lines of treatment would have on Oncopeptides's ability to receive a reimbursed price that reflects its innovation.공고 • Aug 10Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial OfficerOncopeptides AB (publ) announced that the company has appointed Henrik Bergentoft as Chief Financial Officer, CFO. Henrik was most recently CFO at RaySearch Laboratories and brings 20+ years of experience from leading finance roles at both medical and non-medical, publicly listed organizations. He will assume his new position during the fourth quarter, replacing Holger Lembrér.공고 • Aug 08+ 1 more updateOncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO RoleOncopeptides AB (publ) announced that Sofia Heigis who will move from the CCO role to take on the CEO role.공고 • Jun 14Holger Lembrér Will Leave Oncopeptides as Chief Financial OfficerOncopeptides AB (publ) announced that Holger Lembrér, Chief Financial Officer (CFO) has decided to leave Oncopeptides to pursue a new role in another company. Holger was appointed CFO in January 2023. He will continue in his current role until December or until a new CFO takes office. A recruitment process will be initiated immediately.Breakeven Date Change • May 09No longer forecast to breakevenThe 2 analysts covering Oncopeptides no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr45.2m in 2025. New consensus forecast suggests the company will make a loss of kr43.0m in 2025.공고 • Feb 18+ 2 more updatesOncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023Oncopeptides AB (publ) announced that they will report Q2, 2023 results on Aug 10, 2023Reported Earnings • Feb 17Full year 2022 earnings released: kr4.11 loss per share (vs kr19.00 loss in FY 2021)Full year 2022 results: kr4.11 loss per share (improved from kr19.00 loss in FY 2021). Net loss: kr338.0m (loss narrowed 76% from FY 2021). Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.Breakeven Date Change • Feb 12Forecast to breakeven in 2024The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 63% per year to 2023. The company is expected to make a profit of kr53.4m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule.공고 • Jan 12Oncopeptides AB (Publ) Announces Chief Financial Officer ChangesOncopeptides AB (publ.) announced that the company has appointed Holger Lembrer as Chief Financial Officer, CFO. Prior to joining the company, Holger Lembrer was Business Unit CFO at Assa Abloy, and before that Investor Relations Officer, and Financial Controller. He has also been a Senior Auditor at Ernst & Young. Holger Lembrer will assume his new position before the end of February 2023 and will replace Annika Muskantor who has been interim CFO since November 1, 2021.공고 • Jan 05Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific OfficerOncopeptides AB (publ) announced that the Board of Directors has appointed Dr. Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer.공고 • Jan 04Oncopeptides AB (Publ) Announces Executive ChangesOncopeptides AB (publ.) announced that the board of directors has appointed Dr. Monica Shaw as chief executive officer of the company. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer. These changes are effective immediately. Dr. Monica Shaw brings a wealth of executive leadership skills from the pharmaceutical industry, e.g., GSK and LEO Pharma, and has a strong track record from bringing more than 15 products through phase III to successful commercialization, globally and across many geographies. She has a broad therapeutic area knowledge from previous positions as a physician and within industry, including Immunology, Oncology, Virology, Neurology and Rare Diseases.공고 • Dec 15Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023Oncopeptides AB (publ) announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Apr 25, 2023Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 2 highly experienced directors. Independent Director Jennifer Jackson was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Nov 10Forecast to breakeven in 2024The 3 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 64% per year to 2023. The company is expected to make a profit of kr73.4m in 2024. Average annual earnings growth of 87% is required to achieve expected profit on schedule.Reported Earnings • Aug 12Second quarter 2022 earnings released: kr0.79 loss per share (vs kr0.32 loss in 2Q 2021)Second quarter 2022 results: kr0.79 loss per share (down from kr0.32 loss in 2Q 2021). Revenue: kr8.75m (down 87% from 2Q 2021). Net loss: kr59.8m (loss widened 148% from 2Q 2021). Over the next year, revenue is forecast to grow 427%, compared to a 10% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.Breakeven Date Change • Aug 12Forecast to breakeven in 2024The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 68% per year to 2023. The company is expected to make a profit of kr200.2m in 2024. Average annual earnings growth of 30% is required to achieve expected profit on schedule.Buying Opportunity • Jun 28Now 31% undervaluedOver the last 90 days, the stock is up 113%. The fair value is estimated to be kr28.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 126% over the last 3 years. Earnings per share has declined by 17%. For the next 3 years, revenue is forecast to decline by 20% per annum. Earnings is forecast to grow by 26% per annum over the same time period.Reported Earnings • May 06First quarter 2022 earnings released: kr1.31 loss per share (vs kr3.45 loss in 1Q 2021)First quarter 2022 results: kr1.31 loss per share (up from kr3.45 loss in 1Q 2021). Revenue: kr0 (down 100% from 1Q 2021). Net loss: kr98.6m (loss narrowed 58% from 1Q 2021). Profit margin: (up from net loss in 1Q 2021). The move to profitability was driven by lower revenue. Over the next year, revenue is expected to shrink by 54% compared to a 12% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 3 analysts covering Oncopeptides no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr212.5m in 2024. New consensus forecast suggests the company will make a loss of kr146.8m in 2024.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 2 highly experienced directors. Independent Director Jennifer Jackson was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Feb 20Chief Executive Officer recently bought kr2.0m worth of stockOn the 18th of February, Jakob Lindberg bought around 215k shares on-market at roughly kr9.28 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Jakob has been a net seller over the last 12 months, reducing personal holdings by kr14m.공고 • Feb 18Oncopeptides AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023Oncopeptides AB (publ) announced that they will report fiscal year 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023Breakeven Date Change • Feb 17No longer forecast to breakevenThe 4 analysts covering Oncopeptides no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr212.5m in 2024. New consensus forecast suggests the company will make a loss of kr48.0m in 2024.Recent Insider Transactions • Jan 14Independent Chairman of the Board recently bought kr1.4m worth of stockOn the 12th of January, Per Wold-Olsen bought around 186k shares on-market at roughly kr7.60 per share. This was the largest purchase by an insider in the last 3 months. Per has been a buyer over the last 12 months, purchasing a net total of kr1.9m worth in shares.이익 및 매출 성장 예측LSE:0RN4 - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028328-4-7-13312/31/2027239-82-40-73312/31/2026141-147-158-16133/31/202683-221-200-200N/A12/31/202571-250-223-223N/A9/30/202562-268-228-228N/A6/30/202551-267-325-325N/A3/31/202540-278-262-262N/A12/31/202432-285-261-261N/A9/30/202427-282-245-244N/A6/30/202421-263-172-172N/A3/31/202439-246-258-258N/A12/31/202335-249-280-279N/A9/30/202330-259-304-302N/A6/30/202327-307-317-315N/A3/31/20239-310-346-343N/A12/31/20228-338-423-421N/A9/30/2022-14-641-790-789N/A6/30/202241-1,330-1,055-1,055N/A3/31/202299-1,294-1,296-1,296N/A12/31/2021118-1,430-1,517-1,516N/A9/30/2021140-1,549-1,444-1,427N/A6/30/202186-1,155-1,449-1,431N/A3/31/202119-1,532-1,388-1,370N/A12/31/2020N/A-1,595-1,314-1,297N/A9/30/2020N/A-1,327-1,159-1,156N/A6/30/2020N/A-1,133-1,026-1,023N/A3/31/2020N/A-904-863-861N/A12/31/2019N/A-741N/A-691N/A9/30/2019N/A-608N/A-582N/A6/30/2019N/A-512N/A-469N/A3/31/2019N/A-485N/A-436N/A12/31/2018N/A-411N/A-334N/A9/30/2018N/A-368N/A-271N/A6/30/2018N/A-325N/A-262N/A3/31/2018N/A-248N/A-244N/A12/31/2017N/A-250N/A-271N/A9/30/2017N/A-243N/A-270N/A6/30/2017N/A-216N/A-211N/A3/31/2017N/A-172N/A-159N/A12/31/2016N/A-125N/A-104N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 0RN4 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: 0RN4 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: 0RN4 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: 0RN4 의 수익(연간 45.5%)이 UK 시장(연간 4%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 0RN4 의 수익(연간 45.5%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 0RN4의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/10 13:24종가2026/08/07 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Oncopeptides AB (publ)는 7명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Erik HultgårdCarnegie Investment Bank ABPatrik LingDNB CarnegieErik HultgårdDNB Carnegie4명의 분석가 더 보기
Breakeven Date Change • May 19Forecast to breakeven in 2028The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 76% per year to 2027. The company is expected to make a profit of kr41.0m in 2028. Average annual earnings growth of 104% is required to achieve expected profit on schedule.
Breakeven Date Change • Feb 19No longer forecast to breakevenThe 2 analysts covering Oncopeptides no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr39.3m in 2027. New consensus forecast suggests the company will make a loss of kr1.00m in 2027.
공고 • Jan 17Oncopeptides AB (Publ) Provides Sales Guidance for the Fourth Quarter and Full Year 2025Oncopeptides AB (publ) provided sales guidance for the fourth quarter and full year 2025. For the quarter company expects net sales for the second quarter to amount to SEK 18.6 million an increase of 88% versus Fourth Quarter 2024. For the full year, the company expects net sales to amount to 71.2 million SEK, an increase of 125% versus 2024.
Breakeven Date Change • Aug 25Forecast to breakeven in 2027The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% per year to 2026. The company is expected to make a profit of kr13.0m in 2027. Average annual earnings growth of 79% is required to achieve expected profit on schedule.
Breakeven Date Change • May 21Forecast to breakeven in 2027The 3 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 41% per year to 2026. The company is expected to make a profit of kr2.59m in 2027. Average annual earnings growth of 70% is required to achieve expected profit on schedule.
공고 • Apr 05Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024Oncopeptides AB (publ) provided sales guidance for the first quarter of 2024. The company expected net sales to amount to SEK 5.1 million (SEK 1.1 million).
공고 • Jun 17Oncopeptides AB (Publ) Announces Enrollment of First Patient in Oncopeptides' Glioblastoma StudyOncopeptides AB (publ) announced that the first patient has been enrolled in the clinical "Window-of-Opportunity" (WoO) study evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma. The WoO study, named OP-701 (INSULA), represents the first clinical evaluation of a PDC in glioblastoma, marking a major strategic milestone as Oncopeptides expands its core technology platform beyond multiple myeloma. The focused trial will enroll approximately 10 patients to provide initial human proof-of-concept to assess that the company's technology successfully penetrates the human blood-brain barrier (BBB) in glioblastoma patients and have cytotoxic (cell killing) activity in tumor cells. The BBB remains the primary clinical obstacle and causes most traditional oncological drugs to fail in this disease. By utilizing an approved drug from Oncopeptides' platform as a "clinical probe," the study employs an innovative and highly efficient design to capture drug activity directly within the tumor tissue from patients scheduled for surgery for recurrent disease. This approach aims to validate the underlying biological mechanism in a rapid, cost-efficient manner before advancing a PDC asset into formal dose-finding and potential further clinical trials. Glioblastoma is the most aggressive and devastating form of brain cancer, characterized by rapid tumor growth, invariable relapse, and a total lack of curative options, with a median survival rate of just 12–15 months. The global glioblastoma market represents a profound unmet medical need and is estimated to be worth more than 8 billion USD by 2035. Oncopeptides' PDC molecules are believed to be uniquely equipped to pass the blood-brain barrier due to their small size and lipophilicity, entering the target cancer cells freely to deliver their cytotoxic payload directly where it is needed. The trial is conducted at Oslo University Hospital in Norway.
공고 • May 22Oncopeptides AB Announces Publication of Phase 2 Bridge Study Results for Pepaxti in Relapsed Refractory Multiple Myeloma Patients with Renal ImpairmentOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, announced the publication of the results from the Phase 2 BRIDGE (OP-107) clinical study in the peer-reviewed journal Clinical Lymphoma, Myeloma and Leukemia. The prospective, open-label study evaluated the pharmacokinetics (PK), safety, and efficacy of Pepaxti (melflufen) plus dexamethasone in relapsed, refractory multiple myeloma (RRMM) patients with moderate-to-severe renal impairment (RI). Patients with renal insufficiency represent roughly half of all myeloma diagnoses and typically suffer from poorer long-term outcomes and limited clinical options. The final analyses demonstrate that while systemic exposure to the active metabolite melphalan varies based on baseline kidney function, a reduced melflufen starting dose of 30 mg in patients with moderate renal impairment delivers a consistent safety profile, treatment responses, and survival measures aligned with prior trials conducted in less selected populations. Furthermore, exploratory data gathered across the treatment cycles showed that renal function remained stable or slightly improved during therapy, suggesting that Pepaxti does not adversely impact the kidneys at the studied doses. Validated dose optimization: The PK data directly validate the clinical use and efficacy of a 30 mg Pepaxti starting dose for patients with moderate renal impairment (eGFR =30 to <45 mL/min/1.73 m²). Sustained efficacy in fragile populations: Patients with moderate renal impairment achieved an Overall Response Rate (ORR) of 47.6% in Cohort 1a (40 mg starting dose) and 70.0% in Cohort 1b (30 mg starting dose), with a median progression-free survival (PFS) of 8.6 months and 7.7 months, respectively. No new safety signals: Despite advanced renal impairment and high treatment exposure, the safety profile was well-characterized and manageable. The most frequently reported treatment-emergent adverse events were hematological (thrombocytopenia, anemia, and neutropenia), which is consistent with previous clinical trials. The full article, titled "BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function," is available online via Clinical Lymphoma, Myeloma and Leukemia. Pepaxti (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.
Breakeven Date Change • May 19Forecast to breakeven in 2028The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 76% per year to 2027. The company is expected to make a profit of kr41.0m in 2028. Average annual earnings growth of 104% is required to achieve expected profit on schedule.
Reported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: kr25.4m (up 91% from 1Q 2025). Net loss: kr32.2m (loss narrowed 47% from 1Q 2025). Revenue is forecast to grow 64% p.a. on average during the next 2 years, compared to a 11% decline forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
공고 • Apr 16Oncopeptides AB (publ), Annual General Meeting, May 21, 2026Oncopeptides AB (publ), Annual General Meeting, May 21, 2026, at 14:00 W. Europe Standard Time. Location: tandstickspalatset, vastra, tradgardsgatan 15, stockholm Sweden
New Risk • Apr 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 84% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-kr59m). Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr19m net loss in 2 years). Market cap is less than US$100m (kr573.2m market cap, or US$60.8m).
New Risk • Mar 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 84% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-kr59m). Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr19m net loss in 2 years). Market cap is less than US$100m (kr596.9m market cap, or US$64.2m).
공고 • Mar 18Oncopeptides AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 200.389791 million.Oncopeptides AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 200.389791 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 129,283,736 Price\Range: SEK 1.55 Transaction Features: Rights Offering
Reported Earnings • Feb 20Full year 2025 earnings released: kr1.10 loss per share (vs kr1.71 loss in FY 2024)Full year 2025 results: kr1.10 loss per share (improved from kr1.71 loss in FY 2024). Revenue: kr71.1m (up 125% from FY 2024). Net loss: kr249.6m (loss narrowed 12% from FY 2024). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 3.1% decline forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.
New Risk • Feb 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr45m net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (kr749.9m market cap, or US$82.8m).
Breakeven Date Change • Feb 19No longer forecast to breakevenThe 2 analysts covering Oncopeptides no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr39.3m in 2027. New consensus forecast suggests the company will make a loss of kr1.00m in 2027.
공고 • Feb 19+ 4 more updatesOncopeptides AB (publ) to Report Q2, 2026 Results on Aug 27, 2026Oncopeptides AB (publ) announced that they will report Q2, 2026 results on Aug 27, 2026
공고 • Jan 17Oncopeptides AB (Publ) Provides Sales Guidance for the Fourth Quarter and Full Year 2025Oncopeptides AB (publ) provided sales guidance for the fourth quarter and full year 2025. For the quarter company expects net sales for the second quarter to amount to SEK 18.6 million an increase of 88% versus Fourth Quarter 2024. For the full year, the company expects net sales to amount to 71.2 million SEK, an increase of 125% versus 2024.
New Risk • Jan 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr268m Forecast net loss in 2 years: kr4.9m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr228m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr4.9m net loss in 2 years). Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding).
공고 • Jan 16Oncopeptides AB (publ) to Report Fiscal Year 2025 Results on Feb 19, 2026Oncopeptides AB (publ) announced that they will report fiscal year 2025 results on Feb 19, 2026
New Risk • Nov 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr228m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr228m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).
Reported Earnings • Nov 06Third quarter 2025 earnings released: kr0.27 loss per share (vs kr0.29 loss in 3Q 2024)Third quarter 2025 results: kr0.27 loss per share. Revenue: kr20.2m (up 138% from 3Q 2024). Net loss: kr60.9m (loss widened 1.1% from 3Q 2024). Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the United Kingdom.
New Risk • Oct 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-kr67m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr35m net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding).
Recent Insider Transactions • Sep 01Chief Executive Officer recently bought kr250k worth of stockOn the 26th of August, Sofia Heigis bought around 57k shares on-market at roughly kr4.40 per share. This transaction amounted to 65% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Sofia's only on-market trade for the last 12 months.
공고 • Sep 01Oncopeptides AB (publ) Announces the Publication of Two Real-World Evidence (RWE) Abstracts on Pepaxti At the International Myeloma Society Annual MeetingOncopeptides AB (publ) announced the publication of two real-world evidence (RWE) abstracts on Pepaxti at the International Myeloma Society (IMS) Annual Meeting, September 17-20 in Toronto, Canada. As previously communicated, the data were generated through treatment outcomes in real world settings from centers in Valencia, Spain and Bologna, Italy and underscore the growing interest in real-world clinical use of Pepaxti. The Italian study reports an overall response rate (ORR) of 47% in a heavily pretreated patient population with relapsed or refractory multiple myeloma, confirming the efficacy previously demonstrated in the HORIZON trial with a similar safety profile. Importantly, the study demonstrated efficacy in patients treated with novel immunotherapies, underscoring the robust effectiveness of Pepaxti in daily clinical practice. The Spanish study confirms the efficacy of Pepaxti in an even more heavily pretreated patient population where the majority of patients had been exposed to either anti-BCMA or anti-GPRC5D immunotherapy, generating data highly relevant to clinicians seeking guidance for treatment decisions. Both studies confirm Pepaxti's favorable tolerability profile in real-world settings - a key consideration in multiple myeloma where safety challenges are common.
Breakeven Date Change • Aug 25Forecast to breakeven in 2027The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% per year to 2026. The company is expected to make a profit of kr13.0m in 2027. Average annual earnings growth of 79% is required to achieve expected profit on schedule.
Reported Earnings • Aug 22Second quarter 2025 earnings released: kr0.30 loss per share (vs kr0.48 loss in 2Q 2024)Second quarter 2025 results: kr0.30 loss per share (improved from kr0.48 loss in 2Q 2024). Revenue: kr19.2m (up 135% from 2Q 2024). Net loss: kr62.8m (loss narrowed 14% from 2Q 2024). Revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
공고 • Aug 22Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 150.232109 million.Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 150.232109 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 46,947,534 Price\Range: SEK 3.2 Transaction Features: Rights Offering
Buy Or Sell Opportunity • Aug 11Now 21% undervaluedOver the last 90 days, the stock has risen 142% to kr4.71. The fair value is estimated to be kr5.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 8.9% over the last 3 years. Earnings per share has grown by 86%. Revenue is forecast to grow by 569% in 2 years. Earnings are forecast to grow by 73% in the next 2 years.
공고 • Jul 23Oncopeptides AB (publ) Announces Acceptance of Spanish and Italian Real-World Data at IMS Annual MeetingOncopeptides AB (publ) announced that two real-world evidence (RWE) posters have been accepted for presentation at the upcoming International Myeloma Society (IMS) Annual Meeting, taking place in Toronto, Canada on September 17-20. The data were generated through treatment outcomes in real world settings from centers in Valencia, Spain and Bologna, Italy and underscore the growing interest in real-world clinical use of Pepaxti. The accepted posters focus on real-world outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma. While specific results will be shared at the congress, the inclusion of these patient cases reflects the increasing importance of RWE to guide treatment decisions in clinical practice. For a medicine with limited awareness and use to date, real-world data play a key role in building physician confidence and informing market access. The inclusion of these two posters at IMS follows a growing body of independent research that reflects clinical experiences across Europe.
공고 • Jul 10+ 1 more updateOncopeptides AB (Publ) Announces Inclusion of Drug Pepaxti in New Clinical Practice Guidelines from Eha-EmnOncopeptides AB (publ) announced that its drug Pepaxti has been included in new clinical practice guidelines from EHA-EMN for patients with relapsed, refractory multiple myeloma. This marks an important recognition by leading experts of the drug's clinical value and ability to meet an unmet medical need in the treatment of this serious blood cancer. The guidelines are based on a thorough evaluation of clinical evidence by leading experts and aim to support doctors in selecting appropriate therapies for their patients. For patients who have received multiple prior lines of therapy and are triple-class refractory /exposed (TCR/TCE) - meaning their disease no longer responds to three major classes of myeloma drugs - Pepaxti is recommended based on Level 1 evidence, the strongest possible, and has a Grade B recommendation. Furthermore, Pepaxti has also been listed as a treatment option for patients with even more advanced disease, TCR/TCE patients relapsing after immunotherapy with either CART cells or ADC and whose disease no longer responds to four drug classes.
공고 • May 22Oncopeptides AB (publ) Approves Election of Christine Rankin as Board MemberThe Annual General Meeting in Oncopeptides AB (publ) was held on 22 May 2025, approved election of Christine Rankin as board members.
Breakeven Date Change • May 21Forecast to breakeven in 2027The 3 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 41% per year to 2026. The company is expected to make a profit of kr2.59m in 2027. Average annual earnings growth of 70% is required to achieve expected profit on schedule.
Reported Earnings • May 16First quarter 2025 earnings released: kr0.29 loss per share (vs kr0.72 loss in 1Q 2024)First quarter 2025 results: kr0.29 loss per share (improved from kr0.72 loss in 1Q 2024). Revenue: kr13.3m (up 162% from 1Q 2024). Net loss: kr60.7m (loss narrowed 10% from 1Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
공고 • May 15+ 1 more updateOncopeptides AB (publ) to Report Q3, 2025 Results on Nov 05, 2025Oncopeptides AB (publ) announced that they will report Q3, 2025 results on Nov 05, 2025
공고 • May 06Oncopeptides AB's Ordinary Shares to be Deleted from OTC EquityOncopeptides AB (publ) Ordinary Shares will be deleted from OTC Equity effective May 06, 2025, due to inactive security.
공고 • Apr 17Oncopeptides AB (publ), Annual General Meeting, May 22, 2025Oncopeptides AB (publ), Annual General Meeting, May 22, 2025, at 10:00 W. Europe Standard Time. Location: at tandstickspalatset, vastra tradgardsgatan 15, stockholm Sweden
공고 • Apr 16Oncopeptides AB (publ) Announces the Publication of New Real-World Data That Further Support the Effectiveness and Tolerability of Melflufen, Refractory Multiple MyelomaOncopeptides AB (publ) announced the publication of new real-world data that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM). The data were presented in an abstract from the University of Catania, Italy. It highlights treatment outcomes in a single-center real-world setting. The retrospective analysis included eight triple-class refractory RRMM patients who had received a median of 3.5 prior lines of therapy. Notably, several patients presented with high-risk features, including extramedullary disease. Despite this, treatment with Pepaxti in combination with dexamethasone showed an overall response rate (ORR) of 37.5%, with partial responses seen even among patients with advanced disease manifestations. The data underline Pepaxti's role as a viable treatment option for patients with advanced RRMM for patients who have received at least three prior lines of therapy and whose disease has progressed on or after the last therapy.
Board Change • Mar 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 2 highly experienced directors. Independent Director Jennifer Jackson was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Mar 03Oncopeptides AB (publ) to Report Q1, 2025 Results on May 15, 2025Oncopeptides AB (publ) announced that they will report Q1, 2025 results on May 15, 2025
New Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr261m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr261m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (127% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr25m net loss in 3 years). Revenue is less than US$5m (kr32m revenue, or US$2.9m). Market cap is less than US$100m (kr342.6m market cap, or US$31.8m).
Reported Earnings • Mar 02Full year 2024 earnings released: kr1.71 loss per share (vs kr2.76 loss in FY 2023)Full year 2024 results: kr1.71 loss per share. Revenue: kr31.6m (down 10% from FY 2023). Net loss: kr284.6m (loss widened 14% from FY 2023). Revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the United Kingdom.
공고 • Feb 20Oncopeptides AB (publ) to Report Q4, 2024 Results on Feb 27, 2025Oncopeptides AB (publ) announced that they will report Q4, 2024 results at 8:00 AM, Central European Standard Time on Feb 27, 2025
공고 • Feb 06Jarl Ulf Jungnelius Resigns from Oncopeptides AB (publ) Board of DirectorsOncopeptides AB (publ) announced that Jarl Ulf Jungnelius has informed the Board of Directors of his decision to step down from the Bord of Directors of Oncopeptides in which he has served since 2011. This due to personal reasons related to a change of domicile from Sweden.
New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (127% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr131m net loss in 2 years). Revenue is less than US$5m (kr27m revenue, or US$2.4m). Market cap is less than US$100m (kr339.6m market cap, or US$30.6m).
공고 • Jan 27Oncopeptides' Pepaxti Formally Approves for Full Reimbursement in ItalyOncopeptides AB (publ) announced that the positive reimbursement decision for its drug Pepaxti (melflufen) has been published in the Italian Official Journal ("IOJ", It.: Gazetta Ufficiale). This marks the final regulatory step for the drug's upcoming commercialization in Italy, confirming Oncopeptides' expectation of first sales during first half, 2025. With the IOJ publication, Oncopeptides can now initiate the regional access process to bring Pepaxti to patients. The company's goal is to make the treatment available to eligible Italian patients with relapsed and refractory multiple myeloma over the coming months. Italy reports an annual incidence of approximately 6,000 new cases of multiple myeloma, and with about 1,800 patients falling within Pepaxti's target population. 79 patients across 10 Italian hospitals during the clinical development of Pepaxti and 86 treated patients in the Early Access Program (EAP) underscores the clinical experience in the country and high unmet need for the drug. The Early Access program have been closed following the reimbursement. As previously communicated, Oncopeptides is currently in the process of strengthening its presence in Italy by expanding its team and investing in initiatives to raise awareness about Pepaxti and its benefits.
Board Change • Jan 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 2 highly experienced directors. Independent Director Jennifer Jackson was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 08Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.45 loss in 3Q 2023)Third quarter 2024 results: kr0.29 loss per share. Revenue: kr8.51m (up 203% from 3Q 2023). Net loss: kr60.2m (loss widened 49% from 3Q 2023). Revenue is forecast to grow 91% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the United Kingdom.
New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (127% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr134m net loss in 2 years). Share price has been volatile over the past 3 months (9.1% average weekly change). Revenue is less than US$5m (kr21m revenue, or US$2.0m). Market cap is less than US$100m (kr343.4m market cap, or US$32.1m).
Reported Earnings • Aug 19Second quarter 2024 earnings released: kr0.48 loss per share (vs kr0.60 loss in 2Q 2023)Second quarter 2024 results: kr0.48 loss per share. Net loss: kr73.2m (loss widened 30% from 2Q 2023). Revenue is forecast to grow 78% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the United Kingdom.
공고 • Jul 04An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million.An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million on July 2, 2024. Industrifonden Foundation has divested its entire stake in Oncopeptides. An undisclosed buyer completed the acquisition of 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden on July 2, 2024.
Reported Earnings • Jun 04First quarter 2024 earnings released: kr0.75 loss per share (vs kr0.75 loss in 1Q 2023)First quarter 2024 results: kr0.75 loss per share (improved from kr0.75 loss in 1Q 2023). Revenue: kr5.07m (up 351% from 1Q 2023). Net loss: kr67.7m (loss narrowed 4.7% from 1Q 2023). Revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the United Kingdom.
공고 • May 17Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy CongressOncopeptides AB (publ) announced that new scientific data on melflufen, branded in Europe as Pepaxti, has been accepted at the 10th annual World Congress on Cont Cont Cont Controversies in Multiple Myeloma (COMy), to be held on May 23-26. The study, published by a team from institutions across Europe, including the University of Wurzburg and the Institute for Molecular Medicine Finland, focuses on the effectiveness of melflufen and shows promising results for the drug when treating patients with a particularly challenging form of multiple myeloma. The study will be presented to congress attendees through an online oral presentation on May 26. The presentation will be given by Caroline Heckman, from the Institute for Molecular Medicine Finland. Multiple myeloma can be especially difficult to treat in patients who have specific genetic mutations or deletions, such as del(17p) and/or mutations in the TP53 gene. These genetic characteristics are associated with a poorer prognosis and shorter survival rates. The research findings indicate that melflufen is more effective than traditional alkylating agents causing DNA damage and promoting the death of cancer cells lacking a functional so-called p53 protein, which is a common issue in high-risk multiple myeloma cases. The study also highlighted significant changes in gene expression that enhance the drug's impact on cancer cells. Furthermore, patients with the del(17p) genetic abnormality treated with melflufen and dexamethasone showed a longer progression-free survival and higher overall response rate compared to those treated with pomalidomide and dexamethasone in the OP-103 OCEAN trial.
New Risk • May 08New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 133% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (133% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr66m net loss in 3 years). Revenue is less than US$5m (kr35m revenue, or US$3.2m). Market cap is less than US$100m (kr637.2m market cap, or US$58.5m).
New Risk • Apr 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr50m net loss in 3 years). Shareholders have been diluted in the past year (4.7% increase in shares outstanding). Revenue is less than US$5m (kr35m revenue, or US$3.3m). Market cap is less than US$100m (kr511.6m market cap, or US$48.4m).
공고 • Apr 05Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024Oncopeptides AB (publ) provided sales guidance for the first quarter of 2024. The company expected net sales to amount to SEK 5.1 million (SEK 1.1 million).
공고 • Mar 13Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Rights Offering
New Risk • Feb 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr279m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr279m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr50m net loss in 3 years). Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (kr35m revenue, or US$3.4m). Market cap is less than US$100m (kr487.2m market cap, or US$47.1m).
공고 • Feb 24Oncopeptides AB (publ), Annual General Meeting, May 22, 2024Oncopeptides AB (publ), Annual General Meeting, May 22, 2024.
공고 • Dec 16Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier LinesOncopeptides announced that the European Commission has decided to formally approve the company’s application to the European Medicines Agency (EMA) for an extended indication for Pepaxti into earlier lines. The previously communicated decision by Oncopeptides to opt out of the process to extend the indication remains. Oncopeptides has submitted an application to adjust the indication of Pepaxti to the originally approved indication, a process that is expected to be finalized in early 2024. During this time, Oncopeptides will work together with the European Commission, EMA as well as local stakeholders to ensure an efficient removal process for the extended indication.
공고 • Nov 18Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024Oncopeptides AB (publ) announced that they will report Q3, 2024 results on Nov 07, 2024
공고 • Nov 15Oncopeptides Selects to Present Additional Data from Ocean StudyOncopeptides AB (publ) announced that long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at the 65th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego between December 9-12. ASH is the world's professional hematologic society serving both clinicians and scientists around the world who are working to conquer blood diseases. The phase 3 OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.
New Risk • Nov 09New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr304m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr304m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr147m net loss in 2 years). Share price has been volatile over the past 3 months (9.9% average weekly change). Revenue is less than US$5m (kr29m revenue, or US$2.7m). Market cap is less than US$100m (kr661.4m market cap, or US$61.0m).
공고 • Oct 27Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024Oncopeptides AB (publ) announced that they will report Q2, 2024 results at 8:00 AM, Central European Standard Time on Aug 14, 2024
공고 • Oct 21Oncopeptides AB (publ) Announces the Nomination CommitteeOncopeptides AB (publ) announces that the composition of the Nomination Committee has been established. According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2024 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of the end of the third quarter 2023 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors. The Nomination Committee in respect of the annual general meeting 2024 consists of the following persons who together represent approximately 29 percent of the number of shares and votes in the company based on the shareholder information at end of September 2023. Staffan Lindstrand, appointed by HealthCap VI L.P., Patrik Sobocki, appointed by Stiftelsen Industrifonden, Caroline Mebius, appointed by Handelsbanken funds, and Per Wold-Olsen, the Chairman of the Board.
공고 • Oct 12Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024Oncopeptides AB (publ) announced that they will report Q1, 2024 results on May 03, 2024
공고 • Oct 02Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024Oncopeptides AB (publ) announced that they will report fiscal year 2023 final results on Apr 22, 2024
공고 • Sep 21Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024Oncopeptides AB (publ) announced that they will report fiscal year 2023 results on Feb 27, 2024
공고 • Sep 15Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial ResultsOncopeptides AB (publ) announced that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), has, following their scientific assessment, adopted a positive opinion on Oncopeptides' application for earlier lines of treatment for patients with relapsed, refractory multiple myeloma (RRMM). The opinion from the CHMP will now be sent to the European Commission for a final decision. Based on findings from its OCEAN trial, Oncopeptides submitted, on 28 Nov. 2022, an application to extend the therapeutic indication of Pepaxti to the treatment of adult patients with multiple myeloma who have received at least two prior lines of therapies, whose disease is refractory to lenalidomide and the last line of therapy. With their opinion, CHMP recommends that the use of Pepaxti could be expanded to earlier lines of treatment and also peripheral administration, meaning delivery of treatment through peripheral rather than central veins, a less invasive way of administration. Oncopeptides will as a next step assess the current market dynamics of the rapidly evolving multiple myeloma landscape, including the competition in different lines of treatment and the effect that extending Pepaxti into earlier lines of treatment would have on Oncopeptides's ability to receive a reimbursed price that reflects its innovation.
공고 • Aug 10Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial OfficerOncopeptides AB (publ) announced that the company has appointed Henrik Bergentoft as Chief Financial Officer, CFO. Henrik was most recently CFO at RaySearch Laboratories and brings 20+ years of experience from leading finance roles at both medical and non-medical, publicly listed organizations. He will assume his new position during the fourth quarter, replacing Holger Lembrér.
공고 • Aug 08+ 1 more updateOncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO RoleOncopeptides AB (publ) announced that Sofia Heigis who will move from the CCO role to take on the CEO role.
공고 • Jun 14Holger Lembrér Will Leave Oncopeptides as Chief Financial OfficerOncopeptides AB (publ) announced that Holger Lembrér, Chief Financial Officer (CFO) has decided to leave Oncopeptides to pursue a new role in another company. Holger was appointed CFO in January 2023. He will continue in his current role until December or until a new CFO takes office. A recruitment process will be initiated immediately.
Breakeven Date Change • May 09No longer forecast to breakevenThe 2 analysts covering Oncopeptides no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr45.2m in 2025. New consensus forecast suggests the company will make a loss of kr43.0m in 2025.
공고 • Feb 18+ 2 more updatesOncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023Oncopeptides AB (publ) announced that they will report Q2, 2023 results on Aug 10, 2023
Reported Earnings • Feb 17Full year 2022 earnings released: kr4.11 loss per share (vs kr19.00 loss in FY 2021)Full year 2022 results: kr4.11 loss per share (improved from kr19.00 loss in FY 2021). Net loss: kr338.0m (loss narrowed 76% from FY 2021). Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Feb 12Forecast to breakeven in 2024The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 63% per year to 2023. The company is expected to make a profit of kr53.4m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule.
공고 • Jan 12Oncopeptides AB (Publ) Announces Chief Financial Officer ChangesOncopeptides AB (publ.) announced that the company has appointed Holger Lembrer as Chief Financial Officer, CFO. Prior to joining the company, Holger Lembrer was Business Unit CFO at Assa Abloy, and before that Investor Relations Officer, and Financial Controller. He has also been a Senior Auditor at Ernst & Young. Holger Lembrer will assume his new position before the end of February 2023 and will replace Annika Muskantor who has been interim CFO since November 1, 2021.
공고 • Jan 05Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific OfficerOncopeptides AB (publ) announced that the Board of Directors has appointed Dr. Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer.
공고 • Jan 04Oncopeptides AB (Publ) Announces Executive ChangesOncopeptides AB (publ.) announced that the board of directors has appointed Dr. Monica Shaw as chief executive officer of the company. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer. These changes are effective immediately. Dr. Monica Shaw brings a wealth of executive leadership skills from the pharmaceutical industry, e.g., GSK and LEO Pharma, and has a strong track record from bringing more than 15 products through phase III to successful commercialization, globally and across many geographies. She has a broad therapeutic area knowledge from previous positions as a physician and within industry, including Immunology, Oncology, Virology, Neurology and Rare Diseases.
공고 • Dec 15Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023Oncopeptides AB (publ) announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Apr 25, 2023
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 2 highly experienced directors. Independent Director Jennifer Jackson was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Nov 10Forecast to breakeven in 2024The 3 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 64% per year to 2023. The company is expected to make a profit of kr73.4m in 2024. Average annual earnings growth of 87% is required to achieve expected profit on schedule.
Reported Earnings • Aug 12Second quarter 2022 earnings released: kr0.79 loss per share (vs kr0.32 loss in 2Q 2021)Second quarter 2022 results: kr0.79 loss per share (down from kr0.32 loss in 2Q 2021). Revenue: kr8.75m (down 87% from 2Q 2021). Net loss: kr59.8m (loss widened 148% from 2Q 2021). Over the next year, revenue is forecast to grow 427%, compared to a 10% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
Breakeven Date Change • Aug 12Forecast to breakeven in 2024The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 68% per year to 2023. The company is expected to make a profit of kr200.2m in 2024. Average annual earnings growth of 30% is required to achieve expected profit on schedule.
Buying Opportunity • Jun 28Now 31% undervaluedOver the last 90 days, the stock is up 113%. The fair value is estimated to be kr28.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 126% over the last 3 years. Earnings per share has declined by 17%. For the next 3 years, revenue is forecast to decline by 20% per annum. Earnings is forecast to grow by 26% per annum over the same time period.
Reported Earnings • May 06First quarter 2022 earnings released: kr1.31 loss per share (vs kr3.45 loss in 1Q 2021)First quarter 2022 results: kr1.31 loss per share (up from kr3.45 loss in 1Q 2021). Revenue: kr0 (down 100% from 1Q 2021). Net loss: kr98.6m (loss narrowed 58% from 1Q 2021). Profit margin: (up from net loss in 1Q 2021). The move to profitability was driven by lower revenue. Over the next year, revenue is expected to shrink by 54% compared to a 12% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 3 analysts covering Oncopeptides no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr212.5m in 2024. New consensus forecast suggests the company will make a loss of kr146.8m in 2024.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 2 highly experienced directors. Independent Director Jennifer Jackson was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Feb 20Chief Executive Officer recently bought kr2.0m worth of stockOn the 18th of February, Jakob Lindberg bought around 215k shares on-market at roughly kr9.28 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Jakob has been a net seller over the last 12 months, reducing personal holdings by kr14m.
공고 • Feb 18Oncopeptides AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023Oncopeptides AB (publ) announced that they will report fiscal year 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023
Breakeven Date Change • Feb 17No longer forecast to breakevenThe 4 analysts covering Oncopeptides no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr212.5m in 2024. New consensus forecast suggests the company will make a loss of kr48.0m in 2024.
Recent Insider Transactions • Jan 14Independent Chairman of the Board recently bought kr1.4m worth of stockOn the 12th of January, Per Wold-Olsen bought around 186k shares on-market at roughly kr7.60 per share. This was the largest purchase by an insider in the last 3 months. Per has been a buyer over the last 12 months, purchasing a net total of kr1.9m worth in shares.